Apolipoprotein E genetic polymorphisms and the development of nephropathy in type 2 diabetes

Journal of the Medical Association of Thailand

Volumn 96, Issue 9, 2013, Pages 1119-1126

  Satirapoj, Bancha ^a   Supasyndh, Ouppatham ^a   Dispan, Rattanawan ^a   Punpanich, Dollapas ^a   Tribanyatkul, Siriwan ^a   Choovichian, Panbuppa ^a  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

ApoE; Apolipoprotein E polymorphisms; Diabetic nephropathy; Type 2 diabetes

Indexed keywords

ALBUMIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CASE CONTROL STUDY; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ALLELES; APOLIPOPROTEINS E; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK;

EID: 84884139751     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Burrows NR, Li Y, Williams DE. Racial and ethnic differences in trends of end-stage renal disease: United States, 1995 to 2005. Adv Chronic Kidney Dis 2008; 15: 147-152.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
3. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165.
4. Quinn M, Angelico MC, Warram JH, Krolewski AS. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996; 39: 940-945.
5. Utermann G, Kindermann I, Kaffarnik H, Steinmetz A. Apolipoprotein E phenotypes and hyperlipidemia. Hum Genet 1984; 65: 232-236.
6. Coonrod BA, Ellis D, Becker DJ, Bunker CH, Kelsey SF, Lloyd CE, et al. Predictors of micro-albuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 1993; 16: 1376-1383.
7. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158: 998-1004.
8. Eto M, Horita K, Morikawa A, Nakata H, Okada M, Saito M, et al. Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet 1995; 48: 288-292.
9. Chowdhury TA, Dyer PH, Kumar S, Gibson SP, Rowe BR, Davies SJ, et al. Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM. Diabetes 1998; 47: 278-280.
10. Ha SK, Park HS, Kim KW, Kim SJ, Kim DH, Kim JH, et al. Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 1999; 14: 2144-2149.
11. Eto M, Saito M, Okada M, Kume Y, Kawasaki F, Matsuda M, et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 2002; 40: 243-251.
12. Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, et al. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 1998; 31: 666-673.
13. Werle E, Fiehn W, Hasslacher C. Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. Diabetes Care 1998; 21: 994-998.
14. Onuma T, Laffel LM, Angelico MC, Krolewski AS. Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol 1996; 7: 1075-1078.
15. Shcherbak NS. Apolipoprotein E gene polymorphism is not a strong risk factor for diabetic nephropathy and retinopathy in Type I diabetes: case-control study. BMC Med Genet 2001; 2: 8. doi: 10.1186/1471-2350-2-8
16. Hadjadj S, Gallois Y, Simard G, Bouhanick B, Passa P, Grimaldi A, et al. Lack of relationship in long-term type 1 diabetic patients between diabetic nephropathy and polymorphisms in apolipoprotein epsilon, lipoprotein lipase and cholesteryl ester transfer protein. Genetique de la Nephropathie Diabetique Study Group. Donnees Epidemiologiques sur le Syndrome d'Insulino-Resistance Study Group. Nephrol Dial Transplant 2000; 15: 1971-1976.
17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27 (1): S5-S10.
18. Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992; 62: 249-256.
19. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab 2000; 26: 254-264.
20. Saito M, Eto M, Makino I. Triglyceride-rich lipoproteins from apolipoprotein E3/2 subjects with hypertriglyceridemia enhance cholesteryl ester synthesis in human macrophages. Atherosclerosis 1997; 129: 73-77.
21. Suzaki K, Kobori S, Ueno S, Uehara M, Kayashima T, Takeda H, et al. Effects of plasmapheresis on familial type III hyper-lipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis 1990; 80: 181-189.
22. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630.
23. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301.
24. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994; 94: 860-869.
25. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J Biol Chem 2001; 276: 49142-49147.
26. Takemura T, Yoshioka K, Aya N, Murakami K, Matumoto A, Itakura H, et al. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 1993; 43: 918-927.
27. Sato H, Suzuki S, Kobayashi H, Ogino S, Inomata A, Arakawa M. Immunohistological localization of apolipoproteins in the glomeruli in renal disease: specifically apoB and apoE. Clin Nephrol 1991; 36: 127-133.
28. Guan J, Zhao HL, Baum L, Sui Y, He L, Wong H, et al. Apolipoprotein E polymorphism and expression in type 2 diabetic patients with nephropathy: clinicopathological correlation. Nephrol Dial Transplant 2009; 24: 1889-1895.
29. Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47: 199-211.
30. Saito T, Oikawa S, Sato H, Sato T, Ito S, Sasaki J. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features. Kidney Int Suppl 1999; 71: S37-S41.